Barclays PLC Purchases 5,367 Shares of Telomir Pharmaceuticals, Inc. (NASDAQ:TELO)

Barclays PLC lifted its position in shares of Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) by 325.1% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 7,018 shares of the company’s stock after acquiring an additional 5,367 shares during the quarter. Barclays PLC’s holdings in Telomir Pharmaceuticals were worth $45,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in TELO. Geode Capital Management LLC grew its holdings in Telomir Pharmaceuticals by 259.8% during the 3rd quarter. Geode Capital Management LLC now owns 238,737 shares of the company’s stock worth $1,533,000 after acquiring an additional 172,382 shares during the period. State Street Corp increased its holdings in Telomir Pharmaceuticals by 99.1% in the third quarter. State Street Corp now owns 36,094 shares of the company’s stock valued at $232,000 after purchasing an additional 17,967 shares during the last quarter. Suncoast Equity Management lifted its stake in Telomir Pharmaceuticals by 109.9% in the third quarter. Suncoast Equity Management now owns 51,194 shares of the company’s stock valued at $329,000 after buying an additional 26,803 shares during the period. Beaird Harris Wealth Management LLC grew its position in shares of Telomir Pharmaceuticals by 212.9% during the 2nd quarter. Beaird Harris Wealth Management LLC now owns 14,623 shares of the company’s stock worth $70,000 after buying an additional 9,950 shares during the period. Finally, Bank of New York Mellon Corp bought a new stake in shares of Telomir Pharmaceuticals in the 2nd quarter valued at about $241,000.

Telomir Pharmaceuticals Stock Performance

Shares of NASDAQ TELO opened at $5.03 on Friday. The firm has a 50 day moving average price of $4.69 and a 200 day moving average price of $4.79. Telomir Pharmaceuticals, Inc. has a 52-week low of $3.11 and a 52-week high of $20.72.

Telomir Pharmaceuticals (NASDAQ:TELO) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.20) earnings per share for the quarter. On average, sell-side analysts forecast that Telomir Pharmaceuticals, Inc. will post -0.54 earnings per share for the current fiscal year.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.